Prodigy Generics and eVenus launch injectable generic Camptosar in USA

Prodigy Generics, a division of Prodigy Health Supplier Corp (PHS), has launched injectable irinotecan, a generic equivalent of the branded cancer drug Camptosar from pharma giant Pfizer (NYSE: PFE) in the USA.

Prodigy has partnered with eVenus Pharmaceutical Laboratories, a wholly-owned subsidiary of China’s Jiangsu Hengrui Medicine Co, to develop a portfolio of oncology products. Irinotecan is the first of several Abbreviated New Drug Applications being developed through the partnership that will add consistent supply and exceptional value to the US injectable market, which has experienced record levels of shortages in the last year.

Irinotecan is indicated for use in the treatment of cancer, primarily colon cancer. It is used in the FOLFIRI chemotherapy regimen consisting of infusional 5-fluorouracil, leucovorin, and irinotecan. Irinotecan is available in 2ml (20mg per ml) and 5ml (20mg per ml) doses.